News
Better Growth Stock: Novo Nordisk vs. Pfizer
Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO) are two top pharmaceutical companies that are pursuing growth opportunities. Pfizer is looking to build up and diversify its business as its COVID
Where Will UnitedHealth Group Stock Be in 5 Years?
UnitedHealth Group (NYSE: UNH) is one of the largest healthcare companies in the world. It's already a top health insurer in the U.S., but that doesn't mean the company isn't working to be even
2 High-Yield Dividend Stocks to Buy in October
High-yield dividend stocks are a powerful way to boost a portfolio's annual performance. By reinvesting the dividend and regularly buying more shares, these stocks can produce impressive returns
Is Pfizer Stock a Buy Now?
Pfizer (NYSE: PFE) sells a wide variety of medicines across treatment areas such as autoimmune diseases and oncology. But it probably is most known for its leading coronavirus vaccine, which helped
3 Top Stocks to Buy in October and Hold Forever
Healthcare in the United States is big business: Experts believe the system could generate more than $6 trillion in annual spending by 2030. That's an opportunity for investors to find the key
3 Stocks to Buy in October That Could Soar More Than 40% Over the Next 12 Months, According to Wall Street
Is the stock market surge of 2023 running out of steam? That seems to be the case. The S&P 500 has retreated from the lofty levels of just a couple of months ago.
But there are some stocks that
Why Pfizer and BioNTech Stocks Zoomed Higher Today
Americans might not be as coronavirus-weary as some fear. Actually, these days they might be more coronavirus-wary. On the back of early take-up data for the latest COVID-19 vaccines that came out
Where Will Pfizer Be in 5 Years?
Pfizer (NYSE: PFE) is a company that's in the midst of a transition. The COVID-19 vaccine maker benefited from a huge revenue boost due to the pandemic. Now, however, as the government is no longer
Why CureVac Stock Plunged Today
Shares of CureVac (NASDAQ: CVAC) were down 9.1% as of 2:45 p.m. ET Thursday after a German court temporarily suspended the biopharmaceutical company's patent trial against BioNTech (NASDAQ: BNTX).
Why Ginkgo Bioworks Stock Is Surging Higher Today
Ginkgo Bioworks (NYSE: DNA) is having a strong showing today. Specifically, the synthetic biology company's shares were up by 10.1% on heavy volume as of 9:57 a.m. ET Wednesday morning.
What's
Ready to Buy the Dip? UnitedHealth Group Stock Is a Smart Buy
UnitedHealth Group (NYSE: UNH) has seen its shares decline more than 6% so far this year. That may not seem like much of a drop, but for a company as steady as UnitedHealth, that represents a
With New COVID-19 Boosters in Tow, Which Is the Better Buy: Pfizer, BioNtech, or Moderna Stock?
The Food and Drug Administration (FDA) just approved the updated Omicron-adapted COVID-19 booster shots from Moderna (NASDAQ: MRNA) and the COVID-19 booster that Pfizer (NYSE: PFE) and BioNTech
Pfizer Stock: Bear vs. Bull
Pfizer (NYSE: PFE) is a stock that everyone's familiar with, but that doesn't mean that everyone agrees you should buy it. While its promise of steady returns and a decent dividend might be
This Market Could Be Worth $10 Billion by 2030 -- 2 Stocks to Buy Now
Innovation never sleeps in the healthcare sector. At the beginning of this year, there had never been a vaccine approved by the U.S. Food and Drug Administration (FDA) for the prevention of the
2 Dirt Cheap Stocks to Buy With $100
We all love a good bargain, whether we're shopping for food, clothing -- or stocks. And even though the stock market has gained this year -- with the S&P 500 rising in the double digits -- there
3 Top Healthcare Stocks to Buy for September
Healthcare is an evergreen frontier for investing. An endless need for better treatments and cures demands innovation and growth, which isn't a bad place to find long-term winners you can stick in a
Could Pfizer Stock Help You Become A Millionaire?
For any investment, getting it to $1 million can be a lofty goal to set. It's by no means an easy task, and will require a sizable buy-in, lots of patience, and good returns along the way. Below
3 Dividend Stocks That Could Be Ideal Buys for Retirees in September
Inflation is making life harder for everyone, including retirees who need to stretch out their savings to help cover additional costs. One way to help offset rising inflation is to invest in
Coronavirus Cases Are on the Rise -- Should You Buy Vaccine Stocks?
Though the pandemic isn't over, people haven't been rushing out to get coronavirus vaccines these days. This spring, the international public health emergency came to an end, and it looked as if we
3 Reasons to Buy Pfizer Stock
Many investors are having a hard time finding good reasons to invest in Pfizer (NYSE: PFE) right now, at least if we go by the company's performance in the stock market this year. Pfizer's shares
Here's Why the Next 4 Months May Be Critical for Pfizer
Pfizer (NYSE: PFE) offered investors certainty in the earlier stages of the pandemic. People were clamoring for coronavirus vaccines and treatments, and Pfizer became a leader in both markets. Its
3 Dividend Stocks to Buy and Hold Until You Retire
Retirement is a big problem for many Americans. According to a recent poll from BlackRock, just 56% of people believe that they will be able to retire comfortably and have the life they want in
3 Fantastic Stocks to Buy in a New Bull Market
A new bull market is here ... almost. Some maintain that the S&P 500 has already begun a new bull market. Others, though, argue that the index must reach an all-time high first. Either way, many
If You Invested $25,000 in UnitedHealth Stock 10 Years Ago, This Is How Much You Would Have Today
UnitedHealth Group (NYSE: UNH) has been a top healthcare stock to own for years. Today, it's among the largest healthcare companies in the world, worth $475 billion. Although it's a health insurer
Here's Why Pfizer's High-Yield Dividend Could Be Even Safer Than You Might Think
When a company's revenue and earnings plunge, it's understandable if investors begin to worry about its dividend. Pfizer (NYSE: PFE) reported a 53% year-over-year decline in revenue in its latest